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Summary.-A prospective trial with concurrent controls was designed to assess the
effects of specific active immunotherapy in patients receiving intermittent cytotoxic
chemotherapy (DTIC+Vincristine) as an adjuvant to surgery in Stage IIB malignant
melanoma. The treated group received monthly irradiated allogeneic melanoma cells
and BCG, and the controls BCG only. Sixteen patients in the treatment arm had a
median relapse-free interval of 5 months, compared to 8 months in 12 controls given
chemotherapy and BCG, and because of this we felt that continuation of the study
was unjustified on ethical grounds. Although all the controls who relapsed did so at
distant sites, 7/11 patients given specific active immunotherapy relapsed initially
within the lymphatic drainage area of the primary tumour. The median intervals
from starting treatment to relapse at distant sites, and the median survival were
identical in the 2 groups.
We conclude thatimmunotherapycomprising irradiated allogeneic melanoma cells
as employed in this study does not prolong survival in surgically treated Stage IIB
malignant melanoma and may even promote early, local relapse.
CLINICAL involvement of the regional
lymph nodes (Stage IIB) in malignant
melanoma carries a poor prognosis. The
mainstay of treatment remains surgical
excision of the nodes en bloc, but although
this produces good local control of the
disease (Veronesi et al., 1977; McNeer and
Cantin, 1967) most patients eventually die
from distant metastases which were clinic-
ally undetectable at the time of surgery.
Improvement in long-term survival there-
fore requires the suppression of occult
metastases by some form of systemic
therapy deployed as an adjuvant to sur-
gery. Disseminated malignant melanoma
responds poorly to chemotherapy. DTIC
remains the most active single agent,
producing an objective regression rate of
around 20%, although most of these
regressions are partial and transient (Luce,
1972). Combinations ofdrugs, some includ-
ing DTIC, are probably no more active
than DTIC alone, and produce greater
toxicity. Attempts have been made to
improve the response to chemotherapy by
supplementing it with various types of
immunotherapy, and we have treated an
uncontrolled series of 59 patients with
disseminated malignant melanoma, using
a combination of DTIC and specific active
immunotherapy with irradiated allogeneic
melanoma cells (Hedley, McElwain and
Currie, 1977). Although there was no
evidence of an effect on survival, the in-
cidence ofobjective regressions in patients
with early dissemination (i.e. confined to
skin, lymph nodes or lungs) was distinctly
higher than historical or literature con-
trols; an observation similar to that of
Newlands et al. (1976). We therefore felt
that micrometastatic disease may be
similarly or even more responsive, and we
have performed a prospective concurrently
controlled trial of specific active immuno-D. W. HEDLEY, T. J. McELWAIN AND G. A. CURRIE
therapy as an adjuvant to surgery in
melanoma patients with a high risk of
recurrence. We report here the results
obtained in patients withsurgicallytreated
Stage JIB disease.
PATIENTS AND METHODS
Patients. The patients with surgically
treated Stage IIB malignant melanoma were
allocated to treatment or control arms as part
of a much larger and heterogeneous group of
patients with a high risk of recurrent disease
(including those with deeply penetrating or
recurrent primary tumours or following
excision of distant or local cutaneous meta-
stases). This report confines itself to a sub-
group of 28 patients with Stage IIB disease.
Since the overall group of "at-risk" patients
wvas only stratified according to sex before
allocation to treatment or control arms, the
Stage IIB groups were uneven, 16 being in
the treated arm and 12 in the control arm.
None of these patients had received
earlier prophylactic lymph-node dissection,
and all had histologically confirmed clinically
manifest regional lymph-node metastases
treated by radical block dissection within
2 months of entering this study. The treat-
ment arm consisted of 12 men and 4 women,
with a median age of 50, range 19-67, and the
controls, 10 men and 2 women, median age
49, range 25-58.
Patients Aere included in the study if the
following investigations revealed no evidence
of local or distant tumour growth: physical
examination, full blood count, ESR, urea,
electrolytes, calcium, biochemical liver-func-
tion tests, LDH, urine melanogens, chest
X-ray, liver and bone scans and lympho-
graphy if the primary wxas on the leg. The
investigations wvere repeated at 3-monthly
intervals and the patients wvere examined for
evidence of disease every 2 weeks.
Treatmient. All patients received chemo-
therapy, which consisted of DTIC 800 mg/M2
i.v. and Vincristine 1-4 Mg/M2 every 4 weeks,
to a total of 6 courses. The treatment arml
received 2 x 107 irradiated allogeneic melano-
ma cells admixed wvith 50 Mtg percutaneous
BCG (Glaxo) in 1 ml Medium 199 given by
multiple intradermal injection, at monthly
intervals 14 days after the previous chemo-
therapy, to a total of 12 courses. Patients in
the control arm received the BCG alone, given
under exactly the same conditions. Thus the
trial evaluates only the effect of intradermal
irradiated allogeneic tumour cells.
RESULTS
Disease-free interval, measured from
the start of medical treatment, the site of
initial relapse and the survival of patients
who had relapsed, were recorded. Table I
TABLE I. Relapse Rate According to Site
ofPrimary
Site
Head an(I
neck
Limb
Trunk
Unkno-wn
Specific active
immunotherapy ConItrols
NO. Re- No. Re-
enitered lapses entere(l lapses
I 0 :3 0
11
4
0
8
:3
I)
2
1
4
2
0
shows the number of patients who had
relapsed at the time of writing, according
to treatment and site of the primary
tumour. Fig. 1 is a life-table analysis of
relapse-free interval in the 2 groups.
Although the median relapse-free interval
was only 5 months in the group given
specific active immuinotherapy, compared
to 8 months in the case ofthe controls, and
although a slightly smaller proportion of
the controls have relapsed, analysis by the
log-rank method shows that the difference
between these curves is not statistically
significant (P- 0.175). However, these
results raised sufficient ethical doubts to
persuade us to abandon the trial after the
entry of only 28 patients. Of the patients
treated with specific active immuno-
therapy, 7/11 relapsed initially within the
lymphatic drainage area of the primary
tumour (i.e. were regional relapses), while
all of the controls (6/6) relapsed at distant
sites. Four ofthese 7 patients with regional
relapses have since developed distant
metastases, and Fig. 2 shows that the
interval between starting treatment and
the development of distant metastases is
identical in the 2 groups. Sturvival in
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FIG. 1. Life-table analysis of relapse-free interval. Specific active immunotherapy ( 0) vs
controls (f--E). Disease-free.
0
o
0.
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Time(months)
FIG. 2.-Life-table analysis of interval to relapse at distant site. Specific active immunotherapy
(0 0) vs controls (- *). No evidence of distant disease in:, Treatment arm; 0. Controls.
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melanoma is related to the appearance of
distant metastases, and there is no dif-
ference in survival measured from the
start oftreatment in the 2-treatment arms
(Fig. 3). This is further evidence that the
treatment and control groups are com-
parable.
Although the difference in relapse-free
interval between groups does not reach
statistical significance, there is a difference
in the sites ofinitial relapse, as summarized
TABLE II.-Site of Initial Relapse in the
2 Treatment Armis
Cells BCG
Site +BCG alone
Local cutaneous 1 0
Distaint cutaneous 1 1
Regional nodes 6 0
Liver :3 2*
Bone 0 1*
Brain 0 2
Ovary I 1
Regional 7 0
Distant 4 6
* One patient developed simultaneous hepatic and
osseous metastases.
in Table II. This difference is statistically
significant using Fisher's exact test of
proportions (P < 0.05).
D)ISCUSSION
The rationale for this trial of specific
active immunotherapy as an adjuvant
treatment in malignant melanoma (Stage
IIB) was derived from our earlier studies
in patients with disseminated disease
(Currie and McElwain, 1975; Hedley et al.,
1977). Since in patients with "early" dis-
semination (i.e. disease confined to skin,
lymph nodes or lungs) we observed an
objective regression rate of 56% with a
relatively non-toxic combinationofchemo-
therapy and immunotherapy, it seemed
feasible to test this combination for its
capacity to eliminate or delay the growth
of occult metastatic disease. The results of
this adjuvant study indicate that such
optimism was misplaced. Life-table analy-
sis of survival data shows that the treated
Time (months)
FIG. 3.-Life-table analysis of survival. Specific active immunotherapy (0 0 ) vs controls
(U * - *). Alive.
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and control arms are identical. We felt
obliged to abandon the study on ethical
grounds, in view ofthe very short relapse-
free interval in the patients receiving
irradiated allogeneic tumour cells (5
months). Although conventional statistical
methods do not show that this is signifi-
cantly shorter than that in the control
arm (8 months) it was certainly no better,
and we did not feel justified in continuing
the study in order to prove the existence
of a statistically significant harmful effect.
The absence of any beneficial effects and
the possibility ofharm attributable to the
use ofirradiated melanoma cells is remini-
scent ofthe recent smaller study published
by Mclllmurray and his colleagues (1977).
Although their study and ours differ in
many respects the conclusions are similar.
The use of active immunotherapy as an
adjuvant in Stage II malignant melanoma
has so far produced conflicting results.
Concurrently controlled studies such as
that reported by Pinsky et al., (1976) show
that BCG immunotherapy is without
effect. Other series reporting evidence of
clinical benefit (Gutterman, Mavligit and
McBride, 1973) were performed without
concurrent controls, and must therefore
be regarded with somesuspicion (Editorial,
Br. med. J. 1976).
The relapse-free intervals and survival
times in our patients are not strictly com-
parable with those obtained by many other
authors (except perhaps Mclllmurray et
al., 1977) since patient selection was
different. None of our patients had re-
ceived earlier prophylactic lymph-node
surgery and all of them presented with
clinically detectable lymph-node meta-
stases. However, the patterns of relapse
in our patients are intriguing. Radical
block dissection for Stage IIB melanoma
is usually associated withrelapseat distant
sites (Veronesi et al., 1977) and this was
the case in all our control patients. The
very high incidence of local relapse in our
patients receiving irradiated allogeneic
tumour cells is statistically significant, and
suggests that the immunization procedure
is changing the biological behaviour ofthe
tumour. Although we do not have com-
prehensive data on the number ofregional
lymph nodes found to be involved at block
dissection, we do not believe that such a
variable, or variations in surgical tech-
nique, can be responsible, since our
patients were referred by several different
centres, and there is no indication of bias
in the allocation to treatment or control
arms according to the origin of the
patients.
The promotion of early local recurrence
without any effect on distant recurrence
or survival is an observation ripe for
immunological speculation. It is con-
ceivable, for instance, that depot immu-
nization with tumour cells plus BCG might
act as a focus for trapping specifically
allergized effector cells, and thus may
deplete other sites such as the local drain-
age area ofthe excised lymph nodes. Some
form of antigenic overload, such as that
demonstrated by Vaage (1973) in experi-
mental animals, is also a possibility. No
such speculations would be complete
nowadays without mentioning the possible
generation of specific suppressor T cells.
Since we do not feel justified in continuing
this form of treatment in our patients,
opportunities for examining these pos-
sibilities have vanished. However, studies
in progress at other centres could provide
anopportunityforevaluatingsuchpossible
explanations.
The shape and time course of the sur-
vival curves obtained from this study are
remarkably similar to those previously
obtained in patients with disseminated
disease confined to skin, lymph nodes or
lungs (Hedley et al., 1977). This similarity
in biological behaviour may have implica-
tions for the proponents of adjuvant
cytotoxic chemotherapy. Since patients
with "early" dissemination are in this
respect indistinguishable from patients
with clinically undetectable disease, any
statements that the disease in the latter
patients is in any way more amenable to
ablation with systemic therapy must be
regarded with suspicion. Furthermore,
this study may be yet another confirma-
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tion ofwhatseemstobeageneralprinciple:
that adjuvant treatment can only be ex-
pected to raise the cure rate for a particu-
lar tumour when that treatment is cap-
able of producing a high incidence of
complete regression in patients with dis-
seminated disease. The failure of a
chemotherapy-immunotherapy protocol
as an adjunct to surgery in Stage IIB
malignant melanoma reflects its failure in
disseminated disease.
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